Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 11, 2018
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedinUmberto Capasso Palmiero, Lavinia Morosi, Ezia Bello, et al.
Science Translational Medicine|February 28, 2020
High-dose vitamin C enhances cancer immunotherapyAlessandro Magrì, Giovanni Germano, Annalisa Lorenzato, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulationsAndrea Ballerini, Federico Moro, Ilaria Fuso Nerini, et al.
ACS Nano|August 16, 2017
Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular ReleaseDaniele Maiolo, Claudia Pigliacelli, Paola Sánchez Moreno, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|October 15, 2021
Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activityDenise Pinessi, Andrea Resovi, Fabio Sangalli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2021
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case ReportGiovanna Scarfone, Monica Fumagalli, Martina Imbimbo, et al.
Blood Cells, Molecules & Diseases|October 9, 2002
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patientsCarlo B Gambacorti-Passerini, Francesca Rossi, Magda Verga, et al.
Cancer Research|October 3, 2003
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the ratSarah Donald, Richard D Verschoyle, Peter Greaves, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
European Journal of Cancer (Oxford, England : 1990)|October 13, 2012
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myelomaElisa Gallerani, Massimo Zucchetti, Dario Brunelli, et al.
Pageof 10